Avandia News

Glaxo’s Avandia Fails to Benefit Alzheimer’s Patients in Study

-Bloomberg

07/12/2009 - GlaxoSmithKline Plc’s diabetes drug Avandia failed to benefit patients with Alzheimer’s disease, according to a company-funded study.

The findings are another setback for Avandia, once the biggest-selling drug for diabetes in the world, and raise questions about the theory that Alzheimer’s is a form of diabetes of the brain. Sales of Avandia haven’t recovered since a study linked the drug to heart attacks in May 2007. It generated 805 million pounds ($1.3 billion) last year, down 40 percent from a year earlier.

Analysts and investors hoped Avandia would effectively treat Alzheimer’s disease, and estimated it would generate as much as $300 million annually for the condition. London-based Glaxo halted worldwide development of Avandia for Alzheimer’s disease in April, Bloomberg data shows.

Insulin doesn’t work properly in the brains of patients with Alzheimer’s disease, and previous research suggested Avandia improved mental function in patients without a gene variation linked to the disease.

The six-month study of 553 patients with mild to moderate Alzheimer’s disease found Avandia failed to improve cognition, function, behavior or daily activities in people without a strong genetic predisposition. Patients taking Eisai Co.’s Aricept, the best-selling drug for the disease, fared better on tests of global function in the study, suggesting the trial was adequately designed to find a benefit.

The results were presented at the International Conference on Alzheimer’s Disease in Vienna today.

Scientists have said Avandia may work in Alzheimer’s disease by better regulating sugar levels in patient’s brains, much as it helps regulate diabetics’ blood sugar. The medicine may also reduce brain inflammation and restore normal function to damaged energy centers in brain cells, researchers said.

In mid-stage studies, Avandia was as safe as a placebo and added about three points to the patients’ scores on the 70-point cognitive section of the Alzheimer’s Disease Assessment Scale. Patients who benefited the most from the treatment didn’t carry the APOE-4 gene variant, an indicator of susceptibility to the disease that is responsible for about half of Alzheimer’s cases.

If you or a loved one have experienced an Avandia heart attack, or Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia lawyers of Ennis & Ennis, P.A. today about an Avandia lawsuit. Call us toll free for a free, confidential case evaluation or fill out our online Avandia case evaluation form